Clinical Trial Update: Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis

View source ↗

Summary

A completed non-interventional study evaluating ocrelizumab in participants with relapsing-remitting or primary progressive multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Ocrevus (ocrelizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Multiple Sclerosis | Status: COMPLETED